ViewRay Selects Denver for Headquarters

Progressive most cancers remedy firm to leverage Colorado bioscience expertise sources

DENVER, Aug. 8, 2022 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY), a medical machine firm that designs, manufactures, and markets the MRIdian® radiation remedy system, introduced right now that it’s transferring its headquarters to Denver, Colorado because it continues to draw top-tier expertise from the state’s rising medical expertise sector. Occasion particulars to observe:

Remarks by:

• Jared Polis, Governor, State of Colorado
• Michael Hancock, Mayor, Metropolis of Denver
• Scott Drake, President & CEO, ViewRay

In mid-2019, ViewRay established an workplace in Denver beginning with fewer than ten teammates. ViewRay’s presence in Denver has now grown to over 50 teammates with the enlargement of the corporate’s worldwide advertising and marketing, finance, and authorized groups. ViewRay is likely one of the quickest rising corporations within the med-tech sector with plans for appreciable progress in Denver.

ViewRay expects to proceed increasing its Denver crew with further high-paying roles in product improvement, manufacturing, and high quality and, in 2023, the corporate plans so as to add one other constructing targeted on improvement, manufacturing, and doctor coaching.

Colorado is house to a strong bioscience business making the Mile Excessive Metropolis a perfect location to do enterprise and introduce clinicians to life saving radiation remedy. In line with Colorado Bioscience Affiliation:

• Colorado is house to 720 life sciences corporations and organizations.
• Greater than 32,000 individuals are straight employed by the bioscience business, averaging a $96,000 annual wage.
• Metro Denver has the 8^th largest medical machine sector throughout the U.S.

Over the previous 20 years, ViewRay’s CEO, Scott Drake, and the ViewRay govt crew, have created over 3,000 med tech jobs in Colorado.

“We’re proud to welcome ViewRay headquarters to Colorado, an thrilling transfer that brings good-paying jobs to Coloradans,” mentioned Gov. Polis. “As we proceed to avoid wasting individuals cash and help small companies, Colorado stays the very best place to reside, work, and do enterprise.”

“ViewRay relocating to Denver will create extra alternative for our tech-sector expertise base and proceed to raise our group as a middle for healthcare innovation. Guided by the values of a wholesome group and wholesome community-engagement, we could not be prouder that they’ve chosen our nice metropolis to comprehend their bold mission to enhance most cancers remedy expertise and finally, save hundreds of lives,” Denver Mayor Michael B. Hancock mentioned.

“ViewRay is happy that Colorado would be the worldwide headquarters for this modern most cancers remedy. The state is a magnet for gifted professionals and lecturers in our subject and is quick turning into a middle of the worldwide bioscience business,” mentioned Scott Drake President and CEO of ViewRay. “We sit up for rising as an organization, however extra importantly, we’re dedicated to conquering most cancers by re-envisioning radiation remedy as a result of lives rely on it. Sufferers deserve short-course non-invasive remedy with fewer unintended effects and higher high quality of life, whether or not they face complicated or extra frequent types of most cancers. ViewRay is dedicated to delivering that to each affected person who requires remedy.”

About MRIdian
Radiation remedy remedy works by delivering radiation to tumor websites. Nevertheless, clinicians should restrict the quantity of radiation given to the tumor to protect surrounding wholesome tissue and organs. With standard expertise, clinicians achieve this by spreading the quantity of radiation given over a number of weeks bringing the affected person in for 20-30-40 remedies. In brief, they’re confronted with a trade-off between security and effectiveness; in addition to high quality of life primarily based on remedy schedule.

The MRIdian system supplies oncologists excellent anatomical visualization by diagnostic-quality MR photographs and the power to adapt a radiation remedy plan to the focused most cancers with the affected person on the desk. This mixture permits physicians to outline tight remedy margins to keep away from pointless radiation publicity of susceptible organs-at-risk and wholesome tissue and permits the supply of ablative radiation doses in 5 or fewer remedy periods, with out counting on implanted markers. By offering real-time steady monitoring of the goal and organs-at-risk, MRIdian permits automated gating of the radiation beam if the goal strikes outdoors the user-defined margins. This enables for supply of the prescribed dose to the goal, whereas sparing surrounding wholesome tissue and important buildings, which ends up in minimizing toxicities usually related to standard radiation remedy.

Practically 25,000 sufferers have been handled with MRIdian. Presently, 53 MRIdian techniques are put in at hospitals world wide the place they’re used to deal with all kinds of strong tumors and are the main focus of quite a few ongoing analysis efforts. MRIdian has been the topic of lots of of peer-reviewed publications, scientific assembly abstracts, and displays. For a listing of remedy facilities, please go to: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures, and markets the MRIdian MRI-Guided Radiation Remedy System. MRIdian is constructed upon a proprietary high-definition MR imaging system designed from the bottom as much as handle the distinctive challenges and medical workflow for superior radiation oncology. In contrast to MR techniques utilized in diagnostic radiology, MRIdian’s high-definition MR was purpose-built to handle particular challenges, together with beam distortion, pores and skin toxicity, and different considerations that doubtlessly could come up when excessive magnetic fields work together with radiation beams. ViewRay and MRIdian are registered emblems of ViewRay, Inc.

Ahead-Wanting Statements
This press launch incorporates forward-looking statements inside the which means of Part 27A of the Personal Securities Litigation Reform Act. Statements on this press launch that aren’t purely historic are forward-looking statements. Such forward-looking statements embrace, amongst different issues, ViewRay’s monetary steerage for the complete yr 2022, anticipated future orders, anticipated future working and monetary efficiency, remedy outcomes, remedy adoption, innovation, and the efficiency of the MRIdian techniques. Precise outcomes may differ from these projected in any forward-looking statements resulting from quite a few elements. Such elements embrace, amongst others, the power to commercialize the MRIdian Linac System, demand for ViewRay’s merchandise, the power to transform backlog into income, the timing of supply of ViewRay’s merchandise, the timing, size, and severity of the COVID-19 pandemic, together with its impacts throughout our companies on demand, our operations and world provide chains, the outcomes and different uncertainties related to medical trials, the power to boost the extra funding wanted to proceed to pursue ViewRay’s enterprise and product improvement plans, the inherent uncertainties related to creating new merchandise or applied sciences, competitors within the business by which ViewRay operates, and general market circumstances. For an extra description of the dangers and uncertainties that would trigger precise outcomes to vary from these expressed in these forward-looking statements, in addition to dangers regarding ViewRay’s enterprise typically, see ViewRay’s present and future reviews filed with the Securities and Trade Fee, together with its Annual Report on Kind 10-Ok for the fiscal yr ended December 31, 2021 and its Quarterly Stories on Kind 10-Q, as up to date periodically with the Firm’s different filings with the SEC. These forward-looking statements are made as of the date of this press launch, and ViewRay assumes no obligation to replace the forward-looking statements, or to replace the the reason why precise outcomes may differ from these projected within the forward-looking statements, besides as required by legislation.

SOURCE ViewRay, Inc.